Gemphire Therapeutics Inc. 4
4 · Gemphire Therapeutics Inc. · Filed Aug 12, 2016
Insider Transaction Report
Form 4
LICHTINGER PEDRO
Director
Transactions
- Conversion
Common Stock
2016-08-10$6.71/sh+39,274$263,368→ 39,274 total - Conversion
8% Convertible Subordinated Promissory Note
2016-08-10→ 0 totalExercise: $6.71→ Common Stock (39,274 underlying) - Purchase
Common Stock
2016-08-10$10.00/sh+10,000$100,000→ 49,274 total
Footnotes (1)
- [F1]The note was issued in the original principal amount of $250,000. The outstanding principal and $13,370 of accrued interest on the note automatically converted into shares of Common Stock immediately prior to the closing of the Company's initial public offering.